Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%

MAHWAH, N.J., Feb. 13, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch¹ of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin®² Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIA^™ sales data for the 12-month period ending December 2024, the Evoclin® Foam, 1% market³ achieved annual sales of approximately $5.8 million*.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

References:

¹Glenmark's Clindamycin Phosphate Foam, 1% is only approved for the indication(s) listed in Glenmark's approved label.
²All brand names and trademarks are the property of their respective owners.
³Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications.
*IQVIA^™ National Sales Perspectives: Retail & Non-Retail, December 2024

Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/glenmark-pharmaceuticals-inc-usa-launches-clindamycin-phosphate-foam-1-302375903.html

SOURCE Glenmark Pharmaceuticals Ltd